The contribution of Smith et al¹ regarding the risk cancer in women who test negative for a known familial BRCA mutation is extremely valuable for both clinicians and researchers, and deserves critical attention. Indeed, not only the current National Institute for Health and Clinical Excellence guidelines but most other …